medigraphic.com

2001, Number 4

<< Back Next >>

Arch Cardiol Mex 2001; 71 (4)

Importance of angiotensin converting enzyme in coronary circulation

Mauer DK, Exaire MJE, Escalante ABA

Language: Spanish
References: 26
Page: 278-285
PDF size: 93.86 Kb.


ABSTRACT

It has been suggested that angiotensin II can be synthesized by other enzymatic pathways besides angiotensin converting enzyme. We evaluated the importance of angiotensin converting enzyme in the coronary circulation during the development of hypertension. Hearts obtained from normotensive (n = 4) and hypertensive rats (n = 4) as well as from hypertensive rats treated with ramipril (n = 4) were stimulated with either angiotensin II or angiotensin I. In a Langendorff perfusion system, angiotensin II induced a greater dose-dependent coronary vasoconstriction in the hearts of hypertensive rats than in normotensive rats (p ‹ 0.05). Furthermore, angiotensin I also induced coronary vasoconstriction, which was greater in the hearts of hypertensive rats than in normotensive rats (p ‹ 0.05). Acute angiotensin converting enzyme inhibition reduced angiotensin I-induced vasoconstriction by 78% in the hearts of normotensive rats and by 82% in the hypertensive rats (p ‹ 0.05), whereas in vivo angiotensin converting enzyme inhibition potentiated angiotensin I-induced vasoconstriction in the hearts of normotensive and hipertensive rats (p ‹ 0.05). Bradykinin receptor’s blockade decreased ramiprilat’s inhibitory effect on angiotensin I-induced vasoconstriction (p ‹ 0.05). Thus, the present study suggests that, in coronary circulation, angiotensin II synthesis is mainly angiotensin converting enzyme dependent. However, chronic in vivo inhibition could favor induction of other enzymes involved in angiotensin II synthesis. Evenmore, it is possible that the effect of angiotensin converting enzyme inhibition in coronary circulation depends on bradykinin activity.


REFERENCES

  1. Dostal DE, Baker KM: The cardiac renin-angiotensin system. Conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643-650.

  2. Maassen VanDenBrink A, de Vries R, Saxena PR, Shalekamp MA, Danser AH: Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovasc Res 1999; 44(2): 407-415.

  3. Nussberger J, Brunner DB, Waeber B, Brunner HR: Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma. Hypertension 1986; 8: 476-482.

  4. Mento PF, Wilkes BM: Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension 1987; 9(6 Pt 2): III42-III48.

  5. Hollenberg NK: Implications of species difference for clinical investigation. Studies on the renin-angiotensin system. Hypertension 2000; 35(part 2): 150-154.

  6. Dzau V, Sasamura H, Hein L: Heterogeneity of angiotensin synthetic pathways and receptor subtypes: physiological and pharmacological implications. J Hypertens 1993; 11(suppl 3): S13-S18.

  7. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A: Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990; 265(36): 22348-22357.

  8. Akasu M, Urata H, Kinoshita A, Sasaguri M, Ideishi M, Arakawa K: Differences in tissue angiotensin II-forming pathways by species and organs in vitro. Hypertension 1998; 32(3): 514-20.

  9. Liao Y, Husain A: The chymase-angiotensin system in humans: biochemistry, molecular biology and potential role in cardiovascular diseases. Can J Cardiol 1995; 11(Suppl F): 13F-19F.

  10. Linz W, Schölkens BA: A specific B2-bradykinin receptor antagonist HOE140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992; 105(4): 771-772.

  11. Pitt B: The anti-ischemic potential of angiotensin-converting enzyme inhibition: insights from the heart outcomes prevention evaluation trial. Clin Cardiol 2000; 23(7 Suppl 4): IV9-14.

  12. Erdös EG: Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990; 15 (Suppl 6): S20-S24.

  13. Dumoulin MJ, Adam A, Blais C Jr, Lamontagne D: Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res 1998; 38: 229-236.

  14. Carretero OA, Scicli AG: Local hormonal factors (intracrine, autocrine and paracrine) in hypertension. Hypertension 1991; 18(Suppl 3): I58-I69.

  15. Müller DN, Fischli W, Clozel JP, Hilgers KF, Bohlender J, Ménard J, et al: Local angiotensin II generation in the rat heart. Role of renin uptake. Circ Res 1998; 82: 13-20.

  16. Fernández-Alfonso MS, González C: Nitric oxide and the renin-angiotensin system. Is there a physiological interplay between the systems? J Hypertens 1999; 17: 1355-1361.

  17. van Kats JP, Danser AHJ, van Meegen JR, Sassen LMA, Verdouw PD, Schalekamp MA: Angiotensin production by the heart. A quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98: 73-81.

  18. Wei C, Meng QC, Palmer R, Hageman GR, Durand J, Bradley WE, et al: Evidence for angiotensin-converting enzyme and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 1999; 99: 2583-2589.

  19. Nishimura H, Buikema H, Baltatu O, Ganten D, Urata H: Functional evidence for alternative ang II-forming pathways in hamster cardiovascular system. Am J Physiol 1998; 275: H1307-H1312.

  20. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell’Italia LJ: Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997; 273: H1769-H1774.

  21. Wolny A, Clozel J, Rein J, Mory P, Vogt P, Turino M, et al: Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80: 219-227.

  22. Urata H, Healy B, Stewart RW, Bumpus FM, Husain A: Angiotensin II-forming pathways in normal and failing human hearts. Circ Res 1990; 66: 883-890.

  23. Zisman LS, Abraham WT, Meixell GE, Vamvakias BN, Quaife RA, Lowes BD, et al: Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96(3): 1490-1498.

  24. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell’Italia LJ: Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol 1996; 271: H417-H421.

  25. Le Trong H, Neurath H, Woodbury RG: Substrate specificity of the chymotrypsin-like protease in secretory granules isolated from rat mast cells. Proc Natl Acad Sci USA 1987; 84: 364-367.

  26. Nunez E, Hosoya K, Susic D, Frohlich ED: Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997; 29(1 Pt 2): 519-24.




2020     |     www.medigraphic.com